The Ultimate Blood Glucose Monitor Is Finally Here
▼ Summary
– The wearables industry has successfully developed features like step counting and atrial fibrillation detection, but creating a noninvasive, continuous blood glucose monitor has remained a significant challenge.
– Continuous glucose monitors (CGMs) are essential for diabetics but typically require skin penetration, and their use has expanded to non-diabetics for weight management linked to GLP-1 drugs.
– The PreEvnt Isaac, introduced at CES 2026, is a novel device that estimates blood glucose levels by analyzing breath biomarkers like acetone instead of using optical or needle-based methods.
– The device was inspired by the inventor’s grandson with type 1 diabetes and aims to improve quality of life by offering a portable, non-prick monitoring alternative.
– The Isaac is undergoing clinical trials and is being prepared for upcoming FDA regulatory review, following its initial concept showcase at CES 2025.
For countless individuals managing diabetes, the daily routine involves frequent, invasive finger pricks or wearing an implanted sensor. The quest for a truly non-invasive, continuous blood glucose monitor has been a monumental challenge for the wearables industry, one that even tech giants have struggled to solve. This persistent need makes the arrival of a new device at CES 2026 particularly significant. The PreEvnt Isaac represents a potential paradigm shift, moving beyond the skin to use human breath as a window into blood sugar levels.
The device itself is remarkably compact, roughly the size of a coin. Its innovation lies in its method: instead of attempting to measure glucose through the skin with light, it analyzes the volatile organic compounds in a person’s exhaled breath. It specifically looks for biomarkers like acetone, which correlate with rising blood glucose levels. For someone who needs constant monitoring, the ability to wear a small device on a lanyard or keep it in a pocket, without ever needing a needle, could dramatically improve daily life.
This technology is born from personal necessity. The Isaac is named for the inventor’s young grandson, diagnosed with type 1 diabetes as a toddler. Faced with the difficulty of constantly pricking a small child, Bud Wilcox had an insight. He connected the “acetone breath,” a sweet, fruity odor common during diabetic episodes, to the possibility of a breath-based detection system. The concept debuted at CES 2025 and has since progressed to active human clinical trials at Indiana University.
These ongoing trials are a critical step toward seeking authorization from the US Food and Drug Administration, expected in the coming year. The studies are first evaluating the device’s accuracy against traditional monitoring methods in adolescents with type 1 diabetes, with plans to expand to adults with type 2 diabetes. The goal is to generate the robust clinical data required for regulatory approval.
The potential impact extends beyond the diabetic community. With the soaring popularity of GLP-1 medications and dietary approaches focused on blood sugar management for weight loss, non-invasive glucose tracking has become highly sought-after by a broader wellness audience. A device like the Isaac could provide valuable, real-time feedback without any discomfort, offering insights that were previously inaccessible without a prescription for a continuous glucose monitor (CGM). While it may not be integrated into a smartwatch or ring just yet, its standalone form factor presents a compelling and less invasive alternative for millions seeking to understand their metabolic health.
(Source: Wired)
